181 related articles for article (PubMed ID: 30899638)
1. Therapeutic Effect of Cabazitaxel and Blood-Brain Barrier opening in a Patient-Derived Glioblastoma Model.
Sulheim E; Mørch Y; Snipstad S; Borgos SE; Miletic H; Bjerkvig R; Davies CL; Åslund AKO
Nanotheranostics; 2019; 3(1):103-112. PubMed ID: 30899638
[TBL] [Abstract][Full Text] [Related]
2. Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel.
Sémiond D; Sidhu SS; Bissery MC; Vrignaud P
Cancer Chemother Pharmacol; 2013 Sep; 72(3):515-28. PubMed ID: 23820961
[TBL] [Abstract][Full Text] [Related]
3. Development of a hybrid nanocarrier-recognizing tumor vasculature and penetrating the BBB for glioblastoma multi-targeting therapy.
Fan R; Chuan D; Hou H; Chen H; Han B; Zhang X; Zhou L; Tong A; Xu J; Guo G
Nanoscale; 2019 Jun; 11(23):11285-11304. PubMed ID: 31165845
[TBL] [Abstract][Full Text] [Related]
4. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.
Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A
J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic analysis of 111 in-labeled liposomal Doxorubicin in murine glioblastoma after blood-brain barrier disruption by focused ultrasound.
Yang FY; Wang HE; Liu RS; Teng MC; Li JJ; Lu M; Wei MC; Wong TT
PLoS One; 2012; 7(9):e45468. PubMed ID: 23029030
[TBL] [Abstract][Full Text] [Related]
6. Design of multifunctional peptide collaborated and docetaxel loaded lipid nanoparticles for antiglioma therapy.
Kadari A; Pooja D; Gora RH; Gudem S; Kolapalli VRM; Kulhari H; Sistla R
Eur J Pharm Biopharm; 2018 Nov; 132():168-179. PubMed ID: 30244167
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of cabazitaxel in mouse models of pediatric brain tumors.
Girard E; Ditzler S; Lee D; Richards A; Yagle K; Park J; Eslamy H; Bobilev D; Vrignaud P; Olson J
Neuro Oncol; 2015 Jan; 17(1):107-15. PubMed ID: 25140037
[TBL] [Abstract][Full Text] [Related]
8. A polymeric temozolomide nanocomposite against orthotopic glioblastoma xenograft: tumor-specific homing directed by nestin.
Prabhu S; Goda JS; Mutalik S; Mohanty BS; Chaudhari P; Rai S; Udupa N; Rao BSS
Nanoscale; 2017 Aug; 9(30):10919-10932. PubMed ID: 28731079
[TBL] [Abstract][Full Text] [Related]
9. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
[TBL] [Abstract][Full Text] [Related]
10. A nanostructure of functional targeting epirubicin liposomes dually modified with aminophenyl glucose and cyclic pentapeptide used for brain glioblastoma treatment.
Zhang CX; Zhao WY; Liu L; Ju RJ; Mu LM; Zhao Y; Zeng F; Xie HJ; Yan Y; Lu WL
Oncotarget; 2015 Oct; 6(32):32681-700. PubMed ID: 26418720
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of doxorubicin in glioblastoma multiforme following ultrasound-Induced blood-brain barrier disruption as determined by microdialysis.
Lin YL; Wu MT; Yang FY
J Pharm Biomed Anal; 2018 Feb; 149():482-487. PubMed ID: 29175555
[TBL] [Abstract][Full Text] [Related]
12. Targeting glioblastoma-derived pericytes improves chemotherapeutic outcome.
Guerra DAP; Paiva AE; Sena IFG; Azevedo PO; Silva WN; Mintz A; Birbrair A
Angiogenesis; 2018 Nov; 21(4):667-675. PubMed ID: 29761249
[TBL] [Abstract][Full Text] [Related]
13. Charge Conversional Biomimetic Nanocomplexes as a Multifunctional Platform for Boosting Orthotopic Glioblastoma RNAi Therapy.
Liu Y; Zou Y; Feng C; Lee A; Yin J; Chung R; Park JB; Rizos H; Tao W; Zheng M; Farokhzad OC; Shi B
Nano Lett; 2020 Mar; 20(3):1637-1646. PubMed ID: 32013452
[TBL] [Abstract][Full Text] [Related]
14. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
15. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
Karim R; Palazzo C; Evrard B; Piel G
J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies.
Xie B; Wan J; Chen X; Han W; Wang H
Mol Cancer Ther; 2020 Mar; 19(3):822-834. PubMed ID: 31848296
[TBL] [Abstract][Full Text] [Related]
17. Investigation on the effect of nanoparticle size on the blood-brain tumour barrier permeability by in situ perfusion via internal carotid artery in mice.
Kang JH; Cho J; Ko YT
J Drug Target; 2019 Jan; 27(1):103-110. PubMed ID: 29972326
[TBL] [Abstract][Full Text] [Related]
18. Engineered nanoparticles for systemic siRNA delivery to malignant brain tumours.
Karlsson J; Rui Y; Kozielski KL; Placone AL; Choi O; Tzeng SY; Kim J; Keyes JJ; Bogorad MI; Gabrielson K; Guerrero-Cazares H; Quiñones-Hinojosa A; Searson PC; Green JJ
Nanoscale; 2019 Nov; 11(42):20045-20057. PubMed ID: 31612183
[TBL] [Abstract][Full Text] [Related]
19. Inducing a Transient Increase in Blood-Brain Barrier Permeability for Improved Liposomal Drug Therapy of Glioblastoma Multiforme.
Lundy DJ; Lee KJ; Peng IC; Hsu CH; Lin JH; Chen KH; Tien YW; Hsieh PCH
ACS Nano; 2019 Jan; 13(1):97-113. PubMed ID: 30532951
[TBL] [Abstract][Full Text] [Related]
20. Encapsulated
Lin YL; Huang XF; Chang KF; Liao KW; Tsai NM
Int J Nanomedicine; 2020; 15():749-760. PubMed ID: 32099363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
